The UBE2/E2 ubiquitin-conjugating enzyme family at the interface of tumor biology and antitumor immunity: mechanisms, biomarkers, and therapeutic opportunities

While the catalytic role of ubiquitin-conjugating (UBE2/E2) enzymes within the ubiquitin–proteasome system is well established, their substrate-specifying functions in cancer, particularly at the tumor–immune interface, remain comparatively underexplored. In this review, we provide an integrative re-evaluation of the UBE2 family organized around three concepts that, we argue, distinguish recent UBE2 research from earlier descriptive accounts: (i) tumor-context–dependent functional duality, in which the same UBE2 enzyme exerts opposing effects across tissue types and substrate landscapes; (ii) convergence of mechanistically distinct UBE2 members on a small set of shared signaling and immunometabolic nodes; and (iii) the emerging role of UBE2 enzymes at the tumor–immune interface, directly linking UBE2 biology to contemporary immunotherapy paradigms. Building on this framework, we synthesize recent evidence showing how dysregulated UBE2 members shape major cancer hallmarks, including uncontrolled proliferation, oncogenic signaling, metabolic reprogramming, immune evasion, and therapeutic resistance, while emphasizing that most reported phenotypes are derived from a limited set of tumor lineages and should not be uncritically extrapolated to all malignancies. Across tumor settings, multiple UBE2 members converge on PI3K/AKT, MAPK/ERK, NF-κB, HIF-1α, antigen-presentation pathways, checkpoint-ligand regulation, and macrophage polarization. We further discuss the potential of UBE2-based signatures as candidate prognostic and immune-stratification biomarkers. While these associations are biologically compelling, most derive from retrospective cohorts and require prospective, multi-center validation before clinical consideration. We also evaluate current pharmacological strategies targeting UBE2-driven vulnerabilities, including small-molecule inhibitors, natural compounds, and combination approaches with chemotherapy and immune checkpoint blockade. Collectively, this synthesis positions UBE2 enzymes as context-resolved regulators of tumor progression and the immune microenvironment, with growing potential for biomarker-guided therapeutic exploitation in precision cancer immunopharmacology, subject to rigorous prospective validation.